Literature DB >> 10879740

Expression of cyclin-dependent kinase 6 (cdk6) and frequent loss of CD44 in nasal-nasopharyngeal NK/T-cell lymphomas: comparison with CD56-negative peripheral T-cell lymphomas.

H C Lien1, C W Lin, P H Huang, M L Chang, S M Hsu.   

Abstract

Lymphomas involving the nasal and nasopharyngeal region mainly include CD56-positive natural killer (NK)/T-cell lymphomas, CD56-negative peripheral T-cell lymphomas (PTL), and B-cell lymphomas. Among these, the CD56-positive lymphoma, presumably of an NK/T-cell nature, is frequently seen in Asian, Mexican, and South American patients. NK cells are proposed to be closer developmentally to T cells than to other lymphoid cells, because bipotential common progenitor cells of NK/T-cell lineage have been isolated. In this study, we collected 47 cases of nasal lymphoma and investigated the phenotypic difference between NK/T-cell lymphoma and PTL by examining the pattern of the developmentally differentially expressed molecules cdk6 (cyclin-dependent kinase 6), CD44, CD117, and by examining the rearrangement of the T-cell receptor gene (TcR-GR). cdk6, an essential regulator of the cell cycle in G1 progression, was over-expressed in a subset of cortical thymocytes, but absent in mature thymocytes. In contrast, CD44, a glycosylated adhesion molecule, was absent in cortical thymocytes, but present in mature thymocytes and peripheral activated T cells. We found both over-expression of nuclear cdk6 (n-cdk6) and frequent absence of CD44 in nasal CD56-positive NK/T-cell lymphomas, in contrast to most nasal CD56-negative PTL, which were CD44-immunoreactive with weak or no expression of n-cdk6. Almost all tested cases of NK/T-cell lymphoma displayed a germ-line configuration of TcR, without evidence of gene rearrangement. Thus, there seems to be a useful distinction between the classical NK/T type of nasal lymphoma (CD56+/n-cdk6+/CD44-/TcR-GR-) and PTL (CD56-/n-cdk6-/CD44+/TcR-GR+) involving the nasal region. The presence of Epstein-Barr virus does not seem to be a good marker for distinguishing between NK/T lymphoma and PTL involving the nasal region.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10879740     DOI: 10.1038/labinvest.3780093

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  15 in total

Review 1.  CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.

Authors:  A-S Tigan; F Bellutti; K Kollmann; G Tebb; V Sexl
Journal:  Oncogene       Date:  2015-10-26       Impact factor: 9.867

2.  Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.

Authors:  Yana Pikman; Gabriela Alexe; Giovanni Roti; Amy Saur Conway; Andrew Furman; Emily S Lee; Andrew E Place; Sunkyu Kim; Chitra Saran; Rebecca Modiste; David M Weinstock; Marian Harris; Andrew L Kung; Lewis B Silverman; Kimberly Stegmaier
Journal:  Clin Cancer Res       Date:  2016-11-09       Impact factor: 12.531

3.  The CDK6-c-Jun-Sp1-MMP-2 axis as a biomarker and therapeutic target for triple-negative breast cancer.

Authors:  Chi-Wen Luo; Ming-Feng Hou; Chia-Wei Huang; Chun-Chieh Wu; Fu Ou-Yang; Qiao-Lin Li; Cheng-Che Wu; Mei-Ren Pan
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

4.  Restricted killer cell immunoglobulin-like receptor repertoire without T-cell receptor gamma rearrangement supports a true natural killer-cell lineage in a subset of sinonasal lymphomas.

Authors:  C W Lin; W H Lee; C L Chang; J Y Yang; S M Hsu
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

5.  CDK6 coordinates JAK2 V617F mutant MPN via NF-κB and apoptotic networks.

Authors:  Iris Z Uras; Barbara Maurer; Harini Nivarthi; Philipp Jodl; Karoline Kollmann; Michaela Prchal-Murphy; Jelena D Milosevic Feenstra; Markus Zojer; Sabine Lagger; Reinhard Grausenburger; Beatrice Grabner; Raimund Holly; Anoop Kavirayani; Christoph Bock; Heinz Gisslinger; Peter Valent; Robert Kralovics; Veronika Sexl
Journal:  Blood       Date:  2019-01-11       Impact factor: 22.113

6.  Panhandle and reverse-panhandle PCR enable cloning of der(11) and der(other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF-4, and CDK6.

Authors:  Leslie J Raffini; Diana J Slater; Eric F Rappaport; Luca Lo Nigro; Nai-Kong V Cheung; Jaclyn A Biegel; Peter C Nowell; Beverly J Lange; Carolyn A Felix
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

7.  Slit2 inhibits growth and metastasis of fibrosarcoma and squamous cell carcinoma.

Authors:  Hee Kyung Kim; Hong Zhang; Hui Li; Tsung-Teh Wu; Stephen Swisher; Donggou He; Lizhi Wu; Jianmin Xu; Craig A Elmets; Mohammad Athar; Xìao-chun Xu; Hui Xu
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

8.  Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.

Authors:  Iris Z Uras; Gina J Walter; Ruth Scheicher; Florian Bellutti; Michaela Prchal-Murphy; Anca S Tigan; Peter Valent; Florian H Heidel; Stefan Kubicek; Claudia Scholl; Stefan Fröhling; Veronika Sexl
Journal:  Blood       Date:  2016-04-20       Impact factor: 22.113

9.  An extranodal NK/T cell lymphoma, nasal type, with specific immunophenotypic and genotypic features.

Authors:  Panagiotis Katsaounis; Alexandra Alexopoulou; Spyros P Dourakis; Alexandros Smyrnidis; Leonidas Marinos; Anna Filiotou; Athanasios J Archimandritis
Journal:  Int J Hematol       Date:  2008-07-25       Impact factor: 2.490

10.  A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis.

Authors:  Miaofen G Hu; Amit Deshpande; Miriam Enos; Daqin Mao; Elisabeth A Hinds; Guo-fu Hu; Rui Chang; Zhuyan Guo; Marei Dose; Changchuin Mao; Philip N Tsichlis; Fotini Gounari; Philip W Hinds
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.